Company News
TD Cowen Picks Rhythm Pharmaceuticals, $130 Target
TD Cowen names Rhythm Pharmaceuticals as its top biotechnology pick, assigning a $130 price target.
Rhythm reported Phase 2 Imcivree results in Prader‑Willi Syndrome showing a mean BMI reduction of 3%
